COVID-19 preclinical drug development database

Pre-clinical COVID-19 Drug Discovery

Liverpool School of Tropical Medicine

Added 15/05/2020 | Updated 15/05/2020

Project Details

Type of project

  • Tier 1: repurposing existing medicines
  • Tier 2: testing existing molecules
  • Tier 3: discovering and categorising new molecules
  • Target identification or validation
  • Supporting technologies, models and assays

Therapeutic target

  • Preventing infection (prophylaxis or preventing cell entry)
  • Preventing virus replication in early disease
  • Direct acting antiviral
  • Preventing cytokine release syndrome (immunomodulation or suppression)
  • Preventing death (respiratory failure, shock or multiple organ failure)

Type of supporting technology

  • Engineered cells lines
  • Viral isolates
  • Assays and protocols (eg. for virus detection)
  • Animal models

Phase of project

  • High throughput screening
  • Focused compound screening (eg. known antiviral compounds)
  • Lead optimisation and activity validation
  • PK/PD testing and toxicology

Modality (if can be disclosed)*

  • Small molecule

Molecular/cellular target (if known or can be disclosed)*

Partner institutions/organisations

  • University of Liverpool

Key contact

Name: Giancarlo Biagini

Email Address: giancarlo.biagini@lstmed.ac.uk

Phone Number:

Key Collaborators:

Anticipated timeframe of future outputs

1-3 months

This research project is looking for the following:

Seeking further engagement with academic and non-academic partners to explore therapeutic discovery projects and also links with clinical colleagues for onward clinical evaluation of re-purposed mon/combination drugs

Further Details

Abstract or additional information (if available)*

Published outputs (if available)*

Recent publications (albeit they are pre-prints and not yet peer reviewed): Therapeutics (pre-clinical drug discovery/pharmacology): NTZ dose prediction now on MedRxiv - https://www.medrxiv.org/content/10.1101/2020.05.01.20087130v1 Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection https://medrxiv.org/cgi/content/short/2020.04.24.20078741v1 Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics - https://www.medrxiv.org/content/10.1101/2020.04.16.20068379v1

Relevant weblinks